MedPath

Hypertonic Saline Inhalation in Acute Bronchiolitis

Phase 4
Conditions
Acute Bronchiolitis
Interventions
Drug: normal saline and salbutamol
Drug: hypertonic saline and salbutamol
Drug: Hypertonic saline
Registration Number
NCT03880903
Lead Sponsor
Assiut University
Brief Summary

Acute bronchiolitis is a viral infection that occurs in children most commonly in the first 2 years of life and is characterized by respiratory symptoms, resulting in wheezing and/or crackles upon auscultation. It is usually a self limiting illness. However, this condition may be associated with several severe complications, such as apnea,respiratory failure, or secondary bacterial infection

Detailed Description

Acute bronchiolitis is a viral infection that occurs in children most commonly in the first 2 years of life and is characterized by respiratory symptoms, resulting in wheezing and/or crackles upon auscultation. It is usually a self limiting illness. However, this condition may be associated with several severe complications, such as apnea,respiratory failure, or secondary bacterial infection. Bronchiolitis is a significant cause of respiratory disease worldwide. according to the World Health Organization bullet in, an estimated 150 million new cases occur annually; 11-20 million (7-13%) of these cases are severe enough to require hospital admission. Worldwide, 95% of all cases occur in developing countries. Typically, initial clinical manifestations include upper respiratory tract symptoms such as cough, nasal congestion, and low-grade fever lasting 1 to 3 days, followed by expiratory wheezing, nasal flaring, fine crackles, oxygen saturation on presentation\<94%, tachypnea, increased work of breathing, use of accessory muscles, and retractions in some patients. The need for hospitalization depends on the presence of respiratory symptoms (degree of retractions, increased respiratory effort, decreased oxygen saturation), cyanosis, restlessness or lethargy, and underlying disease states, including apnea. Since no definitive antiviral therapy exists for most causes of bronchiolitis, management of these infants should be directed toward symptomatic relief and maintenance of hydration and oxygenation. One medication that has demonstrated promising results in the management of acute bronchiolitis is nebulized hypertonic saline , Its hyperosmolarity helps to absorb water from the mucosal and submucosal space, thereby increasing mucociliary function by clearing fluids accumulated in the airway and mucus plugs in the lungs. Hypertonic saline can also induce cough to help enhance mucus clearance. The American Academy Of Pediatrics guidelines recommend administration of hypertonic saline in hospitalized bronchiolitis patients. The most common dosage studied is hypertonic saline 3% 4 mL per dose inhaled by nebulizer every 4 to 6 hours, which may take ≥24 hours to work and is typically continued while the child is hospitalized.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
75
Inclusion Criteria
  • infants less than 24 months of age with adiagnosis of acute bronchiolitis
Exclusion Criteria
  • other infants and children above 24 months of age
  • patients with other diseases than acute bronchiolitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
normal saline with bronchdilatornormal saline and salbutamolwill recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours
hypertonic saline with bronchodilatorhypertonic saline and salbutamolwill recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours
hypertonic saline onlyHypertonic salinewill recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours
Primary Outcome Measures
NameTimeMethod
Hospital length of stay24 hours

time taken to discharge or ready to be discharged

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath